Microplastics and Misinformation: What Science Really Says
November 12, 2025
Brand Name :
Lomotil
(United States) [Available]Synonyms :
diphenoxylate/atropine
Class :
Gastrointestinal agents; Antidiarrheal drugs; Antimotility agents
Dosage forms & StrengthsÂ
TabletÂ
2.5 mg/0.025 mgÂ
Solution
2.5mg/0.025mg/5mLÂ
diphenoxylate is used in combination with atropine to treat diarrhea
5 mg of diphenoxylate with 0.05 mg of atropine is prescribed every 6 hours as 2 tablets orally
The drug should not be administered more than 20 mg per day
Discontinue the treatment if clinical improvement is not seen within 10 days
Dosage forms & StrengthsÂ
TabletÂ
2.5 mg/0.025 mgÂ
Solution
2.5mg/0.025mg/5mLÂ
Children of 2 to 13 years of age are only administered with a liquid formulation
<2 years- safety and efficacy are not seen for children under two
2 years- 1.5 to 3 ml orally every 6 hours
3 years- 2 to 3 ml orally every 6 hours
4 years- 2 to 4 ml orally every 6 hours
5 years- 2.5 to 4.5 ml orally every 6 hours
6 to 8 years- 2.5 to 5 ml orally every 6 hours
9 to 12 years- 3.5 to 5 ml every orally every 6 hours
Refer to the adult dosingÂ
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased CNS depressive effect when combined with opioid agonists
CNS Depressants: they may increase the CNS depressant effect of antihistamines
CNS Depressants: they may increase the CNS depressant effect of antihistamines
CNS Depressants: they may increase the CNS depressant effect of antihistamines
CNS Depressants: they may increase the CNS depressant effect of antihistamines
CNS Depressants: they may increase the CNS depressant effect of antihistamines
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
hydroxyzine may enhance the CNS depressant effect of CNS depressants
lemborexant may enhance the CNS depressant effect of CNS depressants
CNS depressants may enhance the CNS depressant effect of methotrimeprazine
may increase the CNS depressant effect
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the depressant effect of opioid agonists
may increase the CNS depressant effect of opioid agonists
may increase the CNS depressant effect
may increase the CNS depressant of opioid agonists
may have an increased CNS depressant effect when combined with flunitrazepam
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with methotrimeprazine
may have an increased CNS depressive effect when combined with oxycodone
may have an increased CNS depressive effect when combined with suvorexant
calcium, magnesium, potassium and sodium oxybateÂ
may have an increased CNS depressant effect when combined with oxybate salt products
may have an increasingly adverse effect when combined with ropeginterferon alfa-2b
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may increase the CNS depressant effect of CNS depressants
nalmefene: they may decrease the therapeutic effect of Opioid Agonists
may increase the CNS depressant effect of Buprenorphine
buprenorphine,long-acting injectionÂ
may increase the CNS depressant effect of Buprenorphine
may increase the risk of CNS depression when combined with 1,2-Benzodiazepine
dexmedetomidine: they may increase the CNS depressant effect of CNS Depressants
oxolamine: they may increase the CNS depressant effect of CNS Depressants
clozapine: they may increase the CNS depressant effect of CNS Depressants
nitrazepam: they may increase the CNS depressant effect of CNS Depressants
obinutuzumab: they may increase the CNS depressant effect of CNS Depressants
secretin: they may increase the CNS depressant effect of CNS Depressants
cimetropium: they may increase the CNS depressant effect of CNS Depressants
guanethidine: they may increase the CNS depressant effect of CNS Depressants
potassium phosphate: they may increase the CNS depressant effect of CNS Depressants
amisulpride: they may increase the CNS depressant effect of CNS Depressants
tiotropium: they may increase the CNS depressant effect of CNS Depressants
nitroglycerin: they may increase the CNS depressant effect of CNS Depressants
ramosetron: they may increase the CNS depressant effect of CNS Depressants
cocaine: they may increase the CNS depressant effect of CNS Depressants
linezolid: they may increase the CNS depressant effect of CNS Depressants
oxychlorosene: they may increase the CNS depressant effect of CNS Depressants
abciximab: it may decrease the excretion rate of abacavir CNS depressant
combining CNS depressants with propoxyphene may result in an additive CNS depression
rimonabant has the potential to intensify the effects of additional central nervous system depressants, including alcohol, benzodiazepines, and opioids, resulting in heightened sedation or respiratory depression
benorilate: it may increase the risk of CNS depression
benoxaprofen: it may increase the risk of CNS depression
alpelisib: it may increase the risk of CNS depression
alogliptin: it may increase the risk of CNS depression
albendazole: it may increase the risk of CNS depression
acyclovir: it may increase the risk of CNS depression
benzydamine: it may increase the risk of CNS depression
cannabidiol: it may increase the risk of CNS depression
capsaicin: it may increase the risk of CNS depression
captopril: it may increase the risk of CNS depression
amobarbital: it may decreased the serum concentration of CNS depressants
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
it increases the effect of diphenoxylate by decreasing the metabolism
it increases the effect of atropine when used simultaneously
it increases the toxicity of diphenoxylate through an unknown mechanism
when used with atropine, macimorelin shows unspecified drug interaction
it increases the toxicity of diphenoxylate through an unknown mechanism
when used together with atropine, it shows anticholinergic effects
it increases the toxicity of diphenoxylate through an unknown mechanism
it increases the toxicity of diphenoxylate through an unknown mechanism
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of orphenadrine
it increases the effect of CNS depressants
CNS depressants increase the effect of paraldehyde
it increases the effect of CNS depressants
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the constipation effect of opioid agonist
may increase the CNS depressant effect
CNS depressants increase the effect of flunarizine
CNS depressants increase the effect of orphenadrine
it increases the effect of CNS depressants
CNS depressants increase the CNS depressing effect of paraldehyde
azelastine/fluticasone intranasalÂ
may increase the CNS depressant effect
may increase the CNS depressant effect of flibanserin
may increase the hypertensive effect of Monoamine Oxidase Inhibitors
olopatadine (Nasal): they may increase the CNS depressant effect of CNS Depressants
azelaic acid: they may increase the CNS depressant effect of CNS Depressants
ipratropium: they may increase the CNS depressant effect of CNS Depressants
levosalbutamol: they may increase the CNS depressant effect of CNS Depressants
naltrexone: they may increase the CNS depressant effect of CNS Depressants
furosemide: it may increase the CNS depressant effect of CNS Depressants
aclidinium: they may increase the CNS depressant effect of CNS Depressants
mequitazine: they may increase the CNS depressant effect of CNS Depressants
glycopyrrolate: they may increase the CNS depressant effect of CNS Depressants
chlorthalidone: they may increase the CNS depressant effect of CNS Depressants
revefenacin: they may increase the CNS depressant effect of CNS Depressants
pitolisant: they may increase the CNS depressant effect of CNS Depressants
betahistine: they may increase the CNS depressant effect of CNS Depressants
chloral hydrate: they may increase the CNS depressant effect of CNS Depressants
doxofylline: they may increase the CNS depressant effect of CNS Depressants
may increase the efficacy of each other when combined
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
diphenoxylate, when used with alprazolam, increases sedation
diphenoxylate, when used with baclofen, increases sedation
diphenoxylate, when used with cinnarizine, increases sedation
diphenoxylate, when used with droperidol, increases sedation
diphenoxylate, when used with hydroxyzine, increases sedation
diphenoxylate, when used with lofexidine, increases sedation
diphenoxylate, when used with metaxalone, increases sedation
diphenoxylate, when used with nalbuphine, increases sedation
diphenoxylate, when used with papaverine, increases sedation
diphenoxylate, when used with ziconotide, increases sedation
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
may increase the CNS depressant effect of cannabinoid-containing products
may increase the CNS depressant effect of cannabinoid-containing products
may increase the CNS depressant effect of opioid agonists
may increase the CNS depressant effect of opioid agonists
may increase the CNS depressant effect of opioid agonists
may increase the risk of adverse effect of other CNS depressants
may increase the risk of adverse effect of other CNS depressants
may increase the risk of adverse effect of other CNS depressants
may increase the risk of adverse effect of other CNS depressants
may increase the risk of adverse effect of other CNS depressants
may enhance the adverse/toxic effect of other CNS depressants
may enhance the adverse/toxic effect of other CNS depressants
may enhance the adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the CNS depressant effect of Opioid Agonists
may enhance the CNS depressant effect of Opioid Agonists
may enhance the CNS depressant effect of Opioid Agonists
may enhance the CNS depressant effect of Opioid Agonists
they increase the toxicity of other CNS depressants
they increase the toxicity of other CNS depressants
they increase the toxicity of other CNS depressants
may enhance the risk of adverse effect of amphetamines
may enhance the risk of adverse effect of amphetamines
may enhance the risk of adverse effect of amphetamines
may enhance the risk of adverse effect of amphetamines
may enhance the risk of adverse effect of amphetamines
may increase the CNS depressant effect
may increase the CNS depressant effect
could increase the vasopressor action
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
may have an increased CNS depressant effect when combined with alcohol
may have an increased CNS depressant effect when combined with alcohol
it may enhance the CNS depressant effect
it may enhance the CNS depressant effect
CNS Depressants may enhance the CNS depressant effect of flunarizine
lisuride may enhance the CNS depressant effect of CNS Depressants
lofexidine may enhance the CNS depressant effect of CNS depressants
perampanel may enhance the CNS depressant effect of CNS Depressants
CNS depressants may enhance the sedative effect of rotigotine
CNS Depressants may enhance the CNS depressant effect of thalidomide
CNS depressants increase the CNS depressing effect of brexanolone
CNS depressants increase the CNS depressing effect of alcohol
it increases the effect of CNS depressants
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
CNS depressants increase the toxicity of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of sedation of pramipexole
CNS depressants increase the effect of sedation of ropinirole
may increase the risk of adverse effect of other CNS depressants
may increase the risk of adverse effect of other CNS depressants
may increase the risk of adverse effect of other CNS depressants
may increase the risk of adverse effect of other CNS depressants
may increase the risk of adverse effect of other CNS depressants
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may enhance the activity
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the sedative effect of CNS depressants
may increase the sedative effect of CNS depressants
may enhance the CNS depressant effect of cannabinoid-containing products
may enhance the CNS depressant effect of cannabinoid-containing products
may enhance the adverse/toxic effect of other CNS depressants
may enhance the adverse/toxic effect of other CNS depressants
may enhance the adverse/toxic effect of other CNS depressants
it increases the effect of CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may increase the CNS depressant effect
may increase the toxic effects
may have an increased CNS depressant effect when combined with brexanolone
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
they increase the toxicity of other CNS depressants
they increase the toxicity of other CNS depressants
they increase the toxicity of other CNS depressants
it increases the effect of CNS depressants
it increases the toxicity of CNS depressants
it increases the effect of CNS depressants
may have an increased CNS depressant effect when combined with Cyproheptadine
may increase the toxic effect of CNS depressants
may increase the toxic effect of CNS depressants
may increase the toxic effect of CNS depressants
may increase the toxic effect of CNS depressants
may increase the toxic effect of CNS depressants
may increase the toxic effect of CNS depressants
promethazine/dextromethorphanÂ
may increase the toxic effect of other CNS Depressants
may increase the adverse effect of CNS Depressants
pramipexole: they may increase the sedative effect of CNS Depressants
valerian: they may increase the CNS depressant effect of CNS Depressants
may increase the toxic effect of CNS Depressants
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
acetaminophen/doxylamine/dextromethorphanÂ
may increase the CNS depressant effect of Doxylamine
metyrosine: they may increase the sedative effect of CNS Depressants
chloroprocaine: they may increase the CNS depressant effect of CNS Depressants
kava: they may increase the CNS depressant effect of CNS Depressants
levothyroxine: they may increase the CNS depressant effect of CNS Depressants
mianserin: they may increase the CNS depressant effect of CNS Depressants
ozanimod: they may increase the CNS depressant effect of CNS Depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
benzyl alcohol: they may increase the CNS depressant effect of CNS Depressants
dimethindene: they may increase the CNS depressant effect of CNS Depressants
piribedil: it may increase the CNS depressant effect of CNS Depressants
potassium citrate: they may increase the CNS depressant effect of CNS Depressants
lutropin alfa: they may increase the CNS depressant effect of CNS Depressants
ceritinib: they may increase the CNS depressant effect of CNS Depressants
dasatinib: they may increase the CNS depressant effect of CNS Depressants
flecainide: they may increase the CNS depressant effect of CNS Depressants
halofantrine: they may increase the CNS depressant effect of CNS Depressants
lomitapide: they may increase the CNS depressant effect of CNS Depressants
methadone: they may increase the CNS depressant effect of CNS Depressants
pilsiicainide hydrochloride: they may increase the CNS depressant effect of CNS Depressants
glucagon: they may increase the CNS depressant effect of CNS Depressants
hyaluronidase: they may increase the CNS depressant effect of CNS Depressants
mirabegron: they may increase the CNS depressant effect of CNS Depressants
solriamfetol: they may increase the CNS depressant effect of CNS Depressants
tedizolid: they may increase the CNS depressant effect of CNS Depressants
aminolevulinic acid: they may increase the CNS depressant effect of CNS Depressants
sparsentan: they may increase the CNS depressant effect of CNS Depressants
alfuzosin: they may increase the CNS depressant effect of CNS Depressants
arginine: they may increase the CNS depressant effect of CNS Depressants
dapoxetine: they may increase the CNS depressant effect of CNS Depressants
dexketoprofen: they may increase the CNS depressant effect of CNS Depressants
diacerein: they may increase the CNS depressant effect of CNS Depressants
indoramin: they may increase the CNS depressant effect of CNS Depressants
aliskiren: they may increase the CNS depressant effect of CNS Depressants
lithium: they may increase the CNS depressant effect of CNS Depressants
sacubitril: they may increase the CNS depressant effect of CNS Depressants
aprotinin: they may increase the CNS depressant effect of CNS Depressants
methylphenidate: they may increase the CNS depressant effect of CNS Depressants
molsidomine: they may increase the CNS depressant effect of CNS Depressants
naftopidil: they may increase the CNS depressant effect of CNS Depressants
pholcodine: they may increase the CNS depressant effect of CNS Depressants
urokinase: they may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS depressants
abacavir: it may decrease the excretion rate of abacavir CNS depressant
abatacept: it may decrease the excretion rate of abacavir CNS depressant
acebutolol: it may decrease the excretion rate of abacavir CNS depressant
aceclofenac: it may decrease the excretion rate of abacavir CNS depressant
acemetacin: it may decrease the excretion rate of abacavir CNS depressant
acenocoumarol: it may decrease the excretion rate of abacavir CNS depressant
acetohexamide: it may decrease the excretion rate of abacavir CNS depressant
aldesleukin: it may decrease the excretion rate of abacavir CNS depressant
alefacept: it may decrease the excretion rate of abacavir CNS depressant
allopurinol: it may decrease the excretion rate of abacavir CNS depressant
bacitracin: it may decrease the excretion rate of abacavir CNS depressant
baricitinib: it may decrease the excretion rate of abacavir CNS depressant
benazepril: it may decrease the excretion rate of abacavir CNS depressant
benserazide: it may decrease the excretion rate of abacavir CNS depressant
acetazolamide: it may increase the risk or severity of CNS depression
balsalazide: it may increase the risk or severity of CNS depression
mepyramine: it may increase the risk or severity of CNS depression
acrivastine: it may increase the risk or severity of CNS depression
adenosine: it may increase the risk or severity of CNS depression
ajmaline: it may increase the risk or severity of CNS depression
alfentanil: it may increase the risk or severity of CNS depression
alprazolam: it may increase the risk or severity of CNS depression
baclofen: it may increase the risk or severity of CNS depression
alvimopan: it may increase the risk or severity of CNS depression
bufexamac: it may increase the risk or severity of CNS depression
butabarbital: it may increase the risk or severity of CNS depression
carbidopa: it may increase the risk or severity of CNS depression
carboplatin: it may increase the risk or severity of CNS depression
carmustine: it may increase the risk or severity of CNS depression
carprofen: it may increase the risk or severity of CNS depression
carvedilol: it may increase the risk or severity of CNS depression
dalfampridine: it may increase the risk or severity of CNS depression
cefaclor: it may increase the risk or severity of CNS depression
bedaquiline: it may increase the risk or severity of CNS depression
cariprazine: it may increase the risk or severity of CNS depression
cetirizine: it may increase the risk or severity of CNS depression
celiprolol: it may increase the risk or severity of CNS depression
dabrafenib: it may increase the risk or severity of CNS depression
dapagliflozin: it may increase the risk or severity of CNS depression
alosetron: it may increase the risk or severity of CNS depression
benzphetamine: it may increase the risk or severity of CNS depression
agomelatine: it may increase the risk or severity of CNS depression
metocurine: it may increase the risk or severity of CNS depression
amoxicillin: it may increase the risk or severity of CNS depression
ampicillin: it may increase the risk or severity of CNS depression
anagrelide: it may increase the risk or severity of CNS depression
apomorphine: it may increase the risk or severity of CNS depression
benzylpenicillin: it may increase the risk or severity of CNS depression
amphetamine: it may decreased the serum concentration of CNS depressants
anakinra: it may decreased the serum concentration of CNS depressants
antipyrine: it may decreased the serum concentration of CNS depressants
arbutamine: it may decreased the serum concentration of CNS depressants
arformoterol: it may decreased the serum concentration of CNS depressants
binimetinib: it may increase the metabolism of CNS depressants
bortezomib: it may increase the metabolism of CNS depressants
brivaracetam: it may increase the metabolism of CNS depressants
cenobamate: it may increase the metabolism of CNS depressants
chlordiazepoxide: it may increase the metabolism of CNS depressants
chlorpromazine: it may increase the metabolism of CNS depressants
oxybuprocaine: it may increase the metabolism of CNS depressants
axitinib: it may increase the metabolism of CNS depressants
pergolide: it may increase the risk of CNS depression
boceprevir: it may increase the risk of CNS depression
bosentan: it may increase the risk of CNS depression
bretylium: it may increase the risk of CNS depression
brexpiprazole: it may increase the risk of CNS depression
the sedative property of hyoscine may be increased
this preparation contains diphenhydramine and may enhance the impact of alcohol and other central nervous system depressants, including opioid analgesics, anticonvulsants, antihistamines, antidepressants, antiemetics, anxiolytic sedatives, antipsychotics, and hypnotics
it increases the toxicity of atropine through an unknown mechanism
it increases the toxicity of atropine through an unknown mechanism
it increases the toxicity of atropine through an unknown mechanism
it increases the toxicity of atropine through an unknown mechanism
it increases the effect of CNS depressants
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
it increases the effect of CNS depressants
CNS depressants increases the toxicity of bupivacaine
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of blonanserin
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of oxycodone
CNS depressants increase the effect of zolpidem
CNS depressants increase the effect of zolpidem
CNS depressants increase the effect of suvorexant
it increases the effect of CNS depressants
Actions and Spectrum:Â
diphenoxylate/atropine is a combination medication used to treat diarrhea. It works by slowing down the movement of the intestines, which reduces the frequency and urgency of bowel movements and helps to relieve diarrhea symptoms. The medication contains two active ingredients: diphenoxylate and atropine.Â
diphenoxylate is an opioid agonist that acts on the mu-opioid receptors in the gastrointestinal tract. It works by slowing down the motility of the intestines, reducing the amount of fluid and electrolytes lost through the bowel movements, and improving the consistency of stools. diphenoxylate is structurally like the narcotic pain medication meperidine (Demerol) but has a much lower potential for abuse.Â
atropine is added to the formulation to discourage misuse of diphenoxylate, as it can cause unpleasant side effects such as dry mouth, blurred vision, and urinary retention. Atropine also has some antidiarrheal effects on its own, as it reduces intestinal motility and secretions and can help to relieve cramps and spasms.Â
The combination of diphenoxylate and atropine has a broad spectrum of activity against different types of diarrhea, including acute and chronic diarrhea caused by infectious, inflammatory, or functional disorders. However, it is not recommended for use in patients with bacterial infections or other specific causes of diarrhea, as it may interfere with the elimination of the infectious agent and delay the resolution of the infection.Â
1-10%Â
Abdominal discomfortÂ
Anticholinergic effectsÂ
Blurred visionÂ
Dryness of skin/mouthÂ
NauseaÂ
VomitingÂ
SedationÂ
Frequency not definedÂ
PancreatitisÂ
Toxic megacolonÂ
Diphenoxylate/atropine is contraindicated in children under 6 years of age due to the risk of respiratory depression, coma, and death, especially when overdosed. Extreme caution must be used when administering this medication to pediatric patients, and it should never be used in children under the age of 2. Use only the lowest effective dose for the shortest possible duration to minimize the risk of serious adverse effects.Â
Contraindication/Caution:Â
Allergy or hypersensitivity to diphenoxylate, atropine, or any of the ingredients in the formulation.Â
Caution should also be exercised when using diphenoxylate/atropine in patients with certain medical conditions, such as inflammatory bowel disease, kidney disease, or heart disease, as well as in patients taking other medications that may interact with diphenoxylate/atropine. The medication may cause drowsiness, dizziness, or impaired coordination, so patients should avoid driving or operating heavy machinery until they know how the medication affects them.Â
Pregnancy consideration: diphenoxylate/atropine should be used in pregnancy only if the assumed benefits outweigh potential risksÂ
Breastfeeding warnings: Some of the active metabolites of the diphenoxylate are secreted in breastmilk but are unknown for atropineÂ
Hence consult your physician for the sameÂ
Pregnancy category:Â
Pharmacology:Â
diphenoxylate/atropine is a combination medication used for the treatment of diarrhea. diphenoxylate is an opioid medication that works by slowing down the movement of the intestines and reducing the frequency and volume of bowel movements. Atropine is added to the medication to discourage abuse of diphenoxylate, which can be addictive if taken in large amounts.Â
Pharmacodynamics:Â
diphenoxylate is a synthetic opioid agonist that binds to the mu-opioid receptors in the gastrointestinal tract, which slows down the propulsive contractions of the smooth muscle and reduces the secretions in the intestinal tract. This results in reduced peristalsis and increased transit time, which leads to decreased frequency and volume of bowel movements.Â
atropine is an antimuscarinic agent that works by blocking the action of acetylcholine at muscarinic receptors in the gastrointestinal tract. atropine inhibits the secretions in the intestinal tract and reduces smooth muscle contractions, which results in a further decrease in bowel movement frequency and volume.Â
Pharmacokinetics:Â
diphenoxylate is absorbed slowly and incompletely from the gastrointestinal tract. The drug is metabolized in the liver, primarily by glucuronidation, and the metabolites are excreted in the urine.Â
atropine is rapidly absorbed from the gastrointestinal tract and is widely distributed throughout the body. The drug is metabolized in the liver and excreted primarily in the urine.Â
Administration:Â
diphenoxylate/atropine is available as a tablet and is typically taken orally. The recommended dose for adults is 2 tablets (2.5 mg diphenoxylate/0.025 mg atropine per tablet) four times a day or as directed by a healthcare provider. The medication should be taken with a full glass of water.Â
It is important to follow the dosing instructions provided by the healthcare provider and not exceed the recommended dose. Diphenoxylate has the potential for abuse and addiction, and taking more than the recommended dose or taking it for longer than prescribed can lead to dependence.Â
Patients should not take diphenoxylate/atropine for more than 48 hours without consulting a healthcare provider. If symptoms persist or worsen after 48 hours of treatment, a healthcare provider should be consulted to rule out underlying conditions. Patients should also avoid alcohol while taking diphenoxylate/atropine, as alcohol can increase the sedative effects of the medication.Â
In addition to taking diphenoxylate/atropine as directed, patients should also maintain good hydration by drinking plenty of fluids to replace those lost due to diarrhea. Electrolyte replacement solutions may also be recommended in severe cases of diarrhea.
Patient information leafletÂ
Generic Name: diphenoxylate/atropineÂ
Pronounced: dahy-fen-ok-suh-leyt -atruh-peenÂ
Why do we use diphenoxylate/atropine?Â
diphenoxylate/atropine is used to treat acute or chronic diarrhea in adults. It is a combination medication that contains diphenoxylate, an opioid medication that slows down the movement of the intestines and reduces the frequency and volume of bowel movements, and atropine, which is added to the medication to discourage its abuse.Â
Diarrhea can result from a variety of causes, including infections, medications, and digestive disorders. The goal of treatment is to reduce the frequency and volume of bowel movements and to alleviate associated symptoms such as cramping, abdominal pain, and dehydration.Â
diphenoxylate/atropine can help to slow down the movement of the intestines and reduce the volume and frequency of bowel movements, thereby helping to alleviate the symptoms of diarrhea. atropine is added to the medication to discourage its abuse, as diphenoxylate can be addictive if taken in large amounts.Â